Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone‐refractory prostate carcinoma

Abstract

The combination of TEEC was active in patients with hormone-refractory prostate carcinoma. The regimen was tolerable, with primarily hematologic toxicity. The addition of carboplatin to TEE did not appear to add to the efficacy of the three-drug combination of antimicrotubule agents.